GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tivic Health Systems Inc (NAS:TIVC) » Definitions » Sloan Ratio %

TIVC (Tivic Health Systems) Sloan Ratio % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tivic Health Systems Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Tivic Health Systems's Sloan Ratio for the quarter that ended in Sep. 2024 was 0.00%.

As of Sep. 2024, Tivic Health Systems has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Tivic Health Systems Sloan Ratio % Historical Data

The historical data trend for Tivic Health Systems's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tivic Health Systems Sloan Ratio % Chart

Tivic Health Systems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
-14.78 - - -19.85 7.47

Tivic Health Systems Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Tivic Health Systems's Sloan Ratio %

For the Medical Devices subindustry, Tivic Health Systems's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tivic Health Systems's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tivic Health Systems's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Tivic Health Systems's Sloan Ratio % falls into.



Tivic Health Systems Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Tivic Health Systems's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-8.244--8.511
--0.118)/5.157
=7.47%

Tivic Health Systems's Sloan Ratio for the quarter that ended in Sep. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2024 )
=(-6.421--6.134
-0)/3.394
=-8.46%

Tivic Health Systems's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was -2.243 (Dec. 2023 ) + -1.481 (Mar. 2024 ) + -1.266 (Jun. 2024 ) + -1.431 (Sep. 2024 ) = $-6.42 Mil.
Tivic Health Systems's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2024 was -1.774 (Dec. 2023 ) + -1.666 (Mar. 2024 ) + -1.287 (Jun. 2024 ) + -1.407 (Sep. 2024 ) = $-6.13 Mil.
Tivic Health Systems's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2024 was 0 (Dec. 2023 ) + 0 (Mar. 2024 ) + 0 (Jun. 2024 ) + 0 (Sep. 2024 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tivic Health Systems  (NAS:TIVC) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2024, Tivic Health Systems has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Tivic Health Systems Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Tivic Health Systems's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tivic Health Systems Business Description

Traded in Other Exchanges
N/A
Address
25821 Industrial Boulevard, Suite 100, Hayward, CA, USA, 94545
Tivic Health Systems Inc is a health technology company focused on developing and commercializing non-invasive bioelectronic medicine. The company's platform-based technology activates the body's own healing mechanisms and can be programmed to treat various disease conditions. company's products provide a natural alternative to the standard synthetic chemical methods used by the pharmaceutical industry. ClearUP Sinus Relief, is a first commercial product of the company which is a patented handled device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.
Executives
Sheryle Bolton director 55 ALMADEN BLVD, SAN JOSE CA 95113
Dean Zikria director C/O INTUITY MEDICAL, INC., 3500 WEST WARREN AVENUE, FREMONT CA 94538
Jennifer Ernst director, officer: Chief Executive Officer 750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Blake Gurfein officer: Chief Scientific Officer 750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Ryan Sabia officer: Chief Operating Officer 750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Kimberly Ann Bambach officer: Interim CFO 25821 INDUSTRIAL BLVD., SUITE 100, HAYWARD CA 94545
Karen Drexler director C/O DIADEXUS, INC., 343 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Veronica Cai officer: Chief Financial Officer C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
John Claude 10 percent owner 750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025
Briana Benz officer: Chief Financial Officer 750 MENLO AVENUE, SUITE 200, MENLO PARK CA 94025